Literature DB >> 14982805

Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate.

G Barnaud1, Y Benzerara, J Gravisse, L Raskine, M J Sanson-Le Pors, R Labia, G Arlet.   

Abstract

Enterobacter aerogenes resistant to cefepime (MIC, 32 microg/ml) was isolated from a patient treated with cefepime for an infection caused by a strain of E. aerogenes overproducing its AmpC beta-lactamase (MIC of cefepime, 0.5 microg/ml). The AmpC beta-lactamase of the resistant strain had an L-293-P amino acid substitution and a high k(cat)/K(m) ratio for cefepime. Both of these modifications were necessary for resistance to cefepime.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14982805      PMCID： PMC353102          DOI： 10.1128/AAC.48.3.1040-1042.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Nucleotide sequence of the chromosomal ampC gene of Enterobacter aerogenes.

Authors:  K E Preston; C C Radomski; R A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.

Authors:  W E Sanders; J H Tenney; R E Kessler
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.

Authors:  Sergei B Vakulenko; Dasantila Golemi; Bruce Geryk; Maxim Suvorov; James R Knox; Shahriar Mobashery; Stephen A Lerner
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Regulation of enterobacterial cephalosporinase production: the role of a membrane-bound sensory transducer.

Authors:  N Honoré; M H Nicolas; S T Cole
Journal:  Mol Microbiol       Date:  1989-08       Impact factor: 3.501

7.  Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.

Authors:  G Barnaud; R Labia; L Raskine; M J Sanson-Le Pors; A Philippon; G Arlet
Journal:  FEMS Microbiol Lett       Date:  2001-02-20       Impact factor: 2.742

Review 8.  Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins.

Authors:  R E Hancock; F Bellido
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

9.  beta-Lactamase expression and outer membrane protein changes in cefpirome-resistant and ceftazidime-resistant gram-negative bacteria.

Authors:  L J Piddock; E A Traynor
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

10.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191
View more
  19 in total

1.  Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19.

Authors:  Jun-ichi Wachino; Hiroshi Kurokawa; Satowa Suzuki; Kunikazu Yamane; Naohiro Shibata; Kouji Kimura; Yasuyoshi Ike; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Exact location of the region responsible for the extended substrate spectrum in class C beta-lactamases.

Authors:  Sang Hee Lee; Jung Hun Lee; Myong Jin Heo; Il Kwon Bae; Seok Hoon Jeong; Sun-Shin Cha
Journal:  Antimicrob Agents Chemother       Date:  2007-10       Impact factor: 5.191

3.  Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.

Authors:  Yohei Doi; David L Paterson; Jennifer M Adams-Haduch; Hanna E Sidjabat; Alexandra O'Keefe; Andrea Endimiani; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-05-04       Impact factor: 5.191

4.  In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases.

Authors:  Premavathy Levasseur; Anne-Marie Girard; Christine Miossec; John Pace; Ken Coleman
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

Review 5.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

6.  In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Authors:  João Pires; Magdalena Taracila; Christopher R Bethel; Yohei Doi; Sara Kasraian; Regula Tinguely; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

7.  Characterization of a novel AmpC β-lactamase produced by a carbapenem-resistant Cedecea davisae clinical isolate.

Authors:  Nacim Ammenouche; Hervé Dupont; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

8.  Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop.

Authors:  Sandrine Dahyot; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

9.  Efficacy of piperacillin combined with the Penem beta-lactamase inhibitor BLI-489 in murine models of systemic infection.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 10.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.